期刊文献+

心脏瓣膜置换术后抗凝治疗的健康教育研究 被引量:3

Effect of Anticoagulative Education on the Patients Receiving Anticoagulative Drug Treatment
下载PDF
导出
摘要 目的:探讨少数民族地区进行抗凝教育对接受心脏换瓣术后患者生存质量的影响.方法:对96例接受抗凝药物治疗的换瓣术后患者采用以集体授课为主、单个指导为辅、鼓励看书自学的方式实施心脏换瓣术后抗凝教育培训,并对能够进行电话联系的患者定期给予抗凝治疗指导.结果:受试者在教育培训前的知识总评分(4.82±0.51)分,教育后为(9.37±0.45)分,P<0.05,有显著性差异.自我管理能力改善情况:教育前患者的自我管理能力评分(4.32±1.19)分,教育后为(9.53±0.20)分,P<0.05,因此抗凝教育知识培训效果是很显著的.32例无法定期指导抗凝治疗的患者中有两位发生血栓形成的并发症.结论:教育是提高患者对治疗的依从性和自我管理能力的有效途径.少数民族地区的患者教育水平普遍偏低,对多媒体以图像为主的教学能较好接受,对文字教育的接受程度较低. Objective: To study the effect of anticoagulative education on the patients receiving anticoagdative drug. Methods: 96 cases of patients who were performed heart valve replacement procedures were trained in 3 different ways: group education, individual education and themselves- education in the hospital for 3 to 4 weeks by a team of medical staff . Results: The average test score was (9.37 ± 0.45) after education and higher than before education (4.82 ± 0.51)P 〈 0.05. The self- care skill and knowledge such as self-monitor of bleeding and PT were improved P 〈0.05. Conclusion: Education is an important approach for the patients who received the cardiac operation for learning anticoagulative knowledge and improving the ability of self - management, There is a gocd result for those patients who received multiplemedia education.
出处 《昆明医学院学报》 2005年第3期68-70,共3页 Journal of Kunming Medical College
基金 美国DreyfusHealthFoundation基金会资助(19990712321)
关键词 心脏瓣膜置换术 抗凝教育 抗凝治疗 Valve replacement Anticoagulative education Anticoagulative treatment
  • 相关文献

参考文献6

二级参考文献11

  • 1马西.维生素K依赖因子在凝血酶原酶活性生成中的依从关系[J].中华血液学杂志,1989,10(9):456-458. 被引量:2
  • 2李卓江,吴嘉.凝血酶原片段F1+2、凝血酶原时间比率与口服抗凝治疗[J].临床血液学杂志,1996,9(2):71-73. 被引量:8
  • 3Hirsh J, Dalen JE, David R, et at. Oral anticoagulants medchanical of action, clinical effectiveness, and optimal therapeutic range. Chest, 1998,114(Suppl 5):445s - 469s.
  • 4Ng VL, Levin J, Corash L, et al. Failure of the international normalized ratio to generate consistent results within a local medical community. Am J Clin Pathol, 1993.99:689.
  • 5Lacapra S, Arkel YS, Ku DH. The use of thrombus precursor protein, Ddimer, prothrombin fragment 1.2, and thrombin antithrombin in the exclusion of proximal deep vein thrombosis and pulmonary embolism. Blood Coagul Fibrinolysis, 2000,11:371 - 377.
  • 6Carville DG, Dimitrijevic N, Walsh M, et al. Thrombus precursor protein(TPP) : marker of thrombosis earty in the pathogenesis of myocardial infarction. Clin Chem, 1996,42:1537- 1541.
  • 7Laupaeis A, Albers G, Dalen J, el al. Antithrombotic therapy in atrial fibrillation. Chest, 1998,114(Suppl 5):579s-589s.
  • 8Stein PD, Alpert JS, Dalen JE, et al. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves.Chest, 1998, 114(Suppl 5) :602s - 610s.
  • 9Hirsh J, Dalem JE, Anderson DR, et al. Oral anticoagulants.Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest, 1998, 114: 445S ~ 469S
  • 10许俊堂,胡大一,丛玉隆.心血管疾病的溶栓与抗栓疗法.北京:人民卫生出版社,2000年第一版

共引文献59

同被引文献15

引证文献3

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部